CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Lux Capital

Shahin Farshchi, Partner

Factors to Employ Whilst Evaluating a Business Prospect

Shahin Farshchi

Shahin Farshchi

How do you work with the companies in which you invest? Tell us about your investment style.


My investment style is to teach the founders, which involves driving their talent and leveraging niche technicality to build or conquer market opportunities. We aim to be mentors to the founders to help achieve their maximum potential. Also, we assist them in recruiting, building strategies, and future financing. We stand by them as they seek our partnerships on a strategic and financial aspect.


How do you differentiate between the opportunities that you see?


The way we differentiate is by understanding how we can be a value-add to the company and founders. The first question we ask ourselves is: what is our unique perspective as it relates to the market and the technology that’s being used to achieve the dominant position in the market. Next, we focus on how we can bring resources to the founders in order for them to be successful. So we set apart by understanding what the potential synergies are and matching those opportunities with our own skill-set and resources to optimize the synergies.


What are the key attributes you look at when evaluating a deal?


We look at the founding team, level of cognitive diversity in the team, the team that compliments one another and is aware of their shortcomings. Then, we use their ability to help them overcome the challenges that they would face in the future. In addition, we focus on finding the right technology or an asset that could give them an unparalleled competitive advantage. Last, but foremost, we look for the potential to build a company that is valued by the private and the public market.


How do you work with clients post investment?


• Start to build a personal relationship with the founding team and the early employees of the company.


• Try to understand the questions they are trying to answer; the kind of technical or business related challenges they need to overcome. Later on, we aim to encase them with the best people to continue to do that as the nature of the challenges changes over the lifetime of the company.


• Help layout a plan that would help them achieve their milestones.


"Aim very high, seek to achieve intended goals but while doing that, be wary of what kind of resources you need and what of kind of risks need to be addressed"


• Facilitate them to procure required resources whether it is partnerships or acquiring assets or technologies and financial partners who will take them to the next level.


Please elaborate on the challenges that startups will need to address.


I think the challenges revolve around recruiting leadership and maintaining technical and product-level skill-set of these organizations. There is a lot of competition for talent.


Another challenge I would lay down is the fundraising value of debt. There is an abundant amount of capital available right now for the companies that are in the early stage and in the growth stage and companies in the middle stage who have raised around $20 million to $30 million dollars and are still pre-product stage and need another round of financing to be able to enter the market and achieve their target economics.


What would be a piece of advice that you could impart to the entrepreneurs who look on embarking on a similar venture along the lines of your service?


I would advise founders to aim very high, seek to achieve intended goals but while doing that, be wary of what kind of resources you need and what of kind of risks need to be addressed before you can achieve their goals.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://biotech-startups.lifesciencesreview.com/leadership-perspective/factors-to-employ-whilst-evaluating-a-business-prospect-nwid-813.html